跳至主要内容
临床试验/NCT02226315
NCT02226315终止不适用

A Retrospective Analysis of Fetal Outcome Compared to Massively Parallel Sequencing Test Results Obtained From Multiple Gestation Pregnancies at Increased Risk for Fetal Chromosomal Aneuploidy

Sequenom, Inc.1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2014年8月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
50
试验地点
1
主要终点
Clinical Performance (Sensitivity/Specificity) of MaterniT21 PLUS LDT Assay

研究概览

简要总结

This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk for fetal aneuploidy.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Subject was pregnant with a multiple gestation and received NIPT with the MaterniT21 PLUS LDT and a valid test result is available;
  • Subject was 18 years of age or older at the time of NIPT;
  • Subject provides signed and dated informed consent in English;

排除标准

  • Subjects' treating physician is not located in the United States.

结局指标

主要结局

Clinical Performance (Sensitivity/Specificity) of MaterniT21 PLUS LDT Assay

时间窗: Subjects contacted within 3 years after pregnancy is completed

Results of the MaterniT21 PLUS LDT will be compared to the pregnancy outcome data obtained from the patient

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验